N-(1,3-dioxoisoindol-5-yl)-7,7-dimethyl-2,5-dioxo-1-phenyl-6,8-dihydroquinoline-3-carboxamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: N-(1,3-dioxoisoindol-5-yl)-7,7-dimethyl-2,5-dioxo-1-phenyl-6,8-dihydroquinoline-3-carboxamide
• 化学式: C₂₆H₂₁N₃O₅
• 分子量: 455.5
• InChiKey: RWMBSQLKGMJBSU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  34
• 可旋转键数：
  3
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  113
• 氢给体数：
  2
• 氢受体数：
  5

文献信息

• Phthalimide compounds useful as protein kinase inhibitors
  申请人：Green Jeremy

  公开号：US20050182061A1

  公开（公告）日：2005-08-18

  The present invention provides compounds as inhibitors of protein kinase, particularly inhibitors of AKT, PDK1, p70S6K, or ROCK kinase, mammalian protein kinases involved in proliferative and neurodegenerative disorders. The invention also provides processes for preparing the compounds of the invention, pharmaceutical compositions comprising the compounds, and methods of utilizing those compounds and compositions in the treatment of various disorders.

  本发明提供了作为蛋白激酶抑制剂的化合物，特别是AKT、PDK1、p70S6K或ROCK激酶的抑制剂，这些哺乳动物蛋白激酶参与了增殖性和神经退行性疾病。本发明还提供了制备本发明化合物的工艺、包含本发明化合物的药物组合物，以及利用这些化合物和组合物治疗各种疾病的方法。
• [EN] PHTHALIMIDE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS<br/>[FR] COMPOSES PHTALIMIDE UTILES EN TANT QU'INHIBITEURS DE PROTEINE KINASE
  申请人：VERTEX PHARMA

  公开号：WO2005039564A1

  公开（公告）日：2005-05-06

  The present invention provides compounds of formula I as inhibitors of protein kinase, particularly inhibitors of AKT, PDK1, p70S6K, or ROCK kinase, mammalian protein kinases involved in proliferative and neurodegenerative disorders. The invention also provides processes for preparing the compounds of the invention, pharmaceutical compositions comprising the compounds, and methods of utilizing those compounds and compositions in the treatment of various disorders.
• [EN] PROCESS FOR PREPARING BENZODIAZEPINES<br/>[FR] PROCEDE DE PREPARATION DE BENZODIAZEPINES
  申请人：ARROW THERAPEUTICS LTD

  公开号：WO2005090319A1

  公开（公告）日：2005-09-29

  A process for producing a compound which is a benzodiazepine derivative of formula: (I) wherein: represents or R1 represents C1-6 alkyl, aryl or heteroaryl; each R3 is the same or different and represents halogen, hydroxy, C1-6 alkyl, C1-6 alkoxy, C1-6 alkylthio, C1-6 haloalkyl, C1-6 haloalkoxy, amino, mono(C1-6 alkyl)amino, di(C1-6 alkyl)amino, nitro, cyano, -CO2R/, -CONR/R//, -NH-CO-R/, -S(O)R/, -S(O)2R/, -NH-S(O)2R/, -S(O)NR/R// or -S(O)2NR/R//, wherein each R/ and R// is the same or different and represents hydrogen or C1-6 alkyl; n is from 0 to 3; X represents -NH-, -N(C1-C6 alkyl)-, -CO-, -CO-NR/-, -S(O)- or -S(O)2-, wherein R/ is hydrogen or a C1-C6 alkyl group; and R4 represents hydrogen; or -CO-R4' or -CO-NH-R4', wherein R4' is a C1-C6 alkyl, C1-C6 hydroxyalkyl, aryl, heteroaryl, carbocyclyl or heterocyclyl group, which group is substituted by a C1-C6 hydroxyalkyl, aryl, heteroaryl, carbocyclyl or heterocyclyl group or a -(C1-C4 alkyl)-X1-(C1-C4 alkyl)-X2-(C1-C4 alkyl) group, wherein X1 represents -O-, -S- or -NR/-, wherein R/ represents H or a C1-C4 alkyl group and X2 represents -CO-, -SO- or -SO2-; or R4' represents -A1-Y-A2, wherein: Al is an aryl, heteroaryl, carbocyclyl or heterocyclyl group; Y represents a direct bond or a C1-C4 alkylene, -SO2-, -CO-, -O-, -S or -NR/-, wherein R/ is a C1-C6 alkyl group; and A2 is an aryl, heteroaryl, carbocyclyl or heterocyclyl group; or R4 is a group selected from aryl-C(O)-C(O)-, heteroaryl-C(O)-C(O)-, carbocyclyl-C(O)-C(O)-, heterocyclyl-C(O)-C(O)- and -ZR5, wherein: Z represents -CO-, -S(O)- or -S(O)2-; and R5 represents C1-6 alkyl, hydroxy, C1-6 alkoxy, C1-6 alkylthio, aryl, heteroaryl, carbocyclyl, heterocyclyl, aryl-(C1-6 alkyl)-, heteroaryl-(C1-6 alkyl)-, carbocyclyl-(C1-6 alkyl)-, heterocyclyl-(C1-6 alkyl)-, aryl-(C1-6 alkyl)-O-, heteroaryl-(C1-6 alkyl)-O-, carbocyclyl-(C1-6 alkyl)-O-, heterocyclyl-(C1-6 alkyl)-O- or -NR/R// wherein each R/ and R// is the same or different and represents hydrogen, C1-6 alkyl, carbocyclyl, heterocyclyl, aryl, heteroaryl, aryl-(C1-6 alkyl)-, heteroaryl-(C1-6 alkyl)-, carbocyclyl-(C1-6 alkyl)- or heterocyclyl-(C1-6 alkyl)-; or a pharmaceutically acceptable salt thereof; which process comprises: (a) subjecting a racemic benzodiazepine derivative of formula: (IIa): wherein R1, R3, R4, n and X are as defined above, and R2 represents an amino protecting group, to crystallisation induced dynamic resolution to yield a benzodiazepine derivative of formula (II): wherein, R1, R2, R3, R4, n and X are as defined above; and (b) deprotecting the benzodiazepine derivative of formula (II) as defined above to yield a benzodiazepine derivative of formula (I) or a pharmaceutically acceptable form thereof as defined above.